Lexeo Therapeutics, Inc.

Equities

LXEO

US52886X1072

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-24 EDT			5-day change	1st Jan Change
15.46 ^USD	-0.13%		+11.62%	+15.20%

05-09	Lexeo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-01	Certain Options of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	CI

Lexeo Therapeutics, Inc. announced that it has received $94.999833 million in funding from a group of investors

March 12, 2024

On March 13, 2024, Lexeo Therapeutics, Inc. closed the transaction. The transaction included participation from returning investors Laurion Capital Management LP, Longitude Capital Management Co., LLC, Omega Fund Management, LLC and Woodline Partners LP.

Latest news about Lexeo Therapeutics, Inc.

Lexeo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Certain Options of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	04-30	CI
Certain Common Stock of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	04-30	CI
Lexeo Therapeutics Signs License Deal With Cornell for Potential Friedreich Ataxia Cardiomyopathy Drug	04-22	MT
Lexeo Therapeutics, Inc. Announces Not to Stand for Reelection of Bernard Davitian as Director	04-22	CI
Lexeo Says AAV-Based Gene Therapy Candidate Gets US FDA's Fast Track Designation for Friedreich's Ataxia Cardiomyopathy	04-16	MT
Lexeo Gets FDA Fast-Track Designation for LX2006 in Friedreich's Ataxia Cardiomyopathy	04-16	DJ
Lexeo Therapeutics, Inc. Announces the U.S. Food and Drug Administration Grants Fast Track Designation for LX2006, an Aav-Based Gene Therapy Candidate for the Treatment of Friedreich?s Ataxia Cardiomyopathy	04-16	CI
Lexeo Therapeutics, Inc.(NasdaqGM:LXEO) added to S&P Global BMI Index	03-17	CI
Lexeo Therapeutics Raises $95 Million Via Private Placement of Shares	03-13	MT
Lexeo Therapeutics, Inc. announced that it has received $94.999833 million in funding from a group of investors	03-12	CI
RBC Raises Price Target on Lexeo Therapeutics to $24 From $22, Cites 'Solid' Friedreich's Ataxia Data; Outperform, Speculative Risk Kept	03-12	MT
Lexeo Therapeutics' Q4 Net Loss Narrows; Cash Runway Extended to 2027 -- Shares Jump Pre-Bell	03-11	MT
LEXEO: ENTERED INTO COMMON STOCK PURCHASE AGREEMENT TO…	03-11	RE
Lexeo Therapeutics, Inc. announced that it expects to receive $94.999833 million in funding	03-10	CI
Lexeo Therapeutics Promotes Sandi See Tai to Chief Development Officer, Makes Other Appointments	02-05	MT
Lexeo Therapeutics, Inc. Strengthens Clinical Development Leadership with New Executive Appointments	02-05	CI
Lexeo Soars After Gene Therapy for Cardiac Disorder Receives Orphan Drug, Fast Track Designations	12-18	MT
Lexeo Therapeutics, Inc.(NasdaqGM:LXEO) added to S&P TMI Index	12-18	CI
Top Premarket Decliners	12-13	MT
Chardan Initiates Lexeo Therapeutics With Buy Rating, $23 Price Target	11-28	MT
Stifel Starts Lexeo Therapeutics With Buy Rating, $20 Price Target	11-28	MT
RBC Initiates Lexeo Therapeutics at Outperform, Speculative Risk With $22 Price Target Amid 'Undemanding' Valuation, Upcoming Catalysts	11-28	MT
JPMorgan Starts Lexeo Therapeutics With Overweight Rating, $20 Price Target	11-28	MT
Lexeo Therapeutics Insider Bought Shares Worth $2,499,992, According to a Recent SEC Filing	11-10	MT

Chart Lexeo Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).

Sector

Biotechnology & Medical Research

Calendar

2024-06-25 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.46 USD

Average target price

21.4 USD

Spread / Average Target

+38.42%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LEXEO THERAPEUTICS, INC.	+15.20%	510M
MODERNA, INC.	+67.53%	62.86B
IQVIA HOLDINGS INC.	-0.77%	41.38B
LONZA GROUP AG	+45.66%	40.38B
CELLTRION, INC.	-10.72%	27.64B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.9B
BIO-TECHNE CORPORATION	+4.70%	12.67B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.27B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research